Pyxis Oncology (PYXS) Competitors $1.90 +0.08 (+4.40%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.92 +0.02 (+0.79%) As of 09/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYXS vs. ALMS, PRTA, CRVS, ERAS, ITOS, SLDB, ATXS, NBTX, FULC, and CGEMShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Alumis (ALMS), Prothena (PRTA), Corvus Pharmaceuticals (CRVS), Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Its Competitors Alumis Prothena Corvus Pharmaceuticals Erasca iTeos Therapeutics Solid Biosciences Astria Therapeutics Nanobiotix Fulcrum Therapeutics Cullinan Therapeutics Alumis (NASDAQ:ALMS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Is ALMS or PYXS more profitable? Pyxis Oncology's return on equity of -68.56% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -119.15% -92.50% Pyxis Oncology N/A -68.56%-52.14% Which has better valuation and earnings, ALMS or PYXS? Pyxis Oncology has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/A-$294.23MN/AN/APyxis Oncology$16.15M7.30-$77.33M-$1.60-1.19 Which has more volatility & risk, ALMS or PYXS? Alumis has a beta of -1.4, indicating that its stock price is 240% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Do insiders and institutionals have more ownership in ALMS or PYXS? 39.1% of Pyxis Oncology shares are owned by institutional investors. 40.7% of Alumis shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer ALMS or PYXS? Alumis presently has a consensus target price of $20.17, suggesting a potential upside of 360.43%. Pyxis Oncology has a consensus target price of $7.75, suggesting a potential upside of 307.89%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alumis is more favorable than Pyxis Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Pyxis Oncology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer ALMS or PYXS? In the previous week, Pyxis Oncology had 1 more articles in the media than Alumis. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for Alumis. Alumis' average media sentiment score of 1.19 beat Pyxis Oncology's score of 1.00 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPyxis Oncology beats Alumis on 7 of the 13 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.87M$2.56B$5.80B$10.17BDividend YieldN/A57.23%5.73%4.61%P/E Ratio-1.1923.2874.8626.39Price / Sales7.30689.98544.60190.76Price / CashN/A27.5625.8129.91Price / Book0.945.4013.256.28Net Income-$77.33M$32.95M$3.29B$270.38M7 Day Performance3.83%-0.53%0.07%1.89%1 Month Performance54.47%4.23%4.59%6.01%1 Year Performance-47.37%-2.81%72.95%25.26% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology2.6912 of 5 stars$1.90+4.4%$7.75+307.9%-49.7%$112.87M$16.15M-1.1960ALMSAlumis3.4432 of 5 stars$4.32-4.2%$20.17+366.8%-62.2%$469.33MN/A0.00N/APositive NewsPRTAProthena3.4318 of 5 stars$8.49-0.7%$19.75+132.6%-63.1%$460.25M$10.34M-1.51130News CoverageAnalyst RevisionCRVSCorvus Pharmaceuticals2.4646 of 5 stars$5.90-4.2%$15.00+154.2%+15.3%$459.01MN/A-5.8430Positive NewsERASErasca2.3736 of 5 stars$1.55-3.7%$3.71+139.6%-46.1%$456.71MN/A-3.44120Analyst DowngradeITOSiTeos Therapeutics3.4477 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsSLDBSolid Biosciences3.1358 of 5 stars$5.13-6.7%$15.00+192.4%-30.8%$428.28M$8.09M-1.83100Positive NewsAnalyst DowngradeATXSAstria Therapeutics2.8514 of 5 stars$7.43-1.2%$29.00+290.3%-33.8%$424.39MN/A-3.7030Positive NewsNBTXNanobiotix0.6401 of 5 stars$8.71+0.1%$8.00-8.2%+88.3%$417.11M$39.18M0.00100Upcoming EarningsShort Interest ↑FULCFulcrum Therapeutics2.6096 of 5 stars$7.27-5.1%$7.57+4.1%+122.3%$414.34M$80M-5.96100News CoveragePositive NewsShort Interest ↓CGEMCullinan Therapeutics2.1908 of 5 stars$6.84-2.1%$26.80+291.8%-64.6%$412.93MN/A-2.1230 Related Companies and Tools Related Companies ALMS Alternatives PRTA Alternatives CRVS Alternatives ERAS Alternatives ITOS Alternatives SLDB Alternatives ATXS Alternatives NBTX Alternatives FULC Alternatives CGEM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYXS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | SponsoredThe End of Elon Musk…?Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
